Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [RNA-seq]

ABSTRACT: HBS/AS01 adjuvanted vaccine induces changes in the chromatin structure in monocytes impacting their gene expression profiles, an effect that lasts until 6 months post vaccination

ORGANISM(S): Homo sapiens

PROVIDER: GSE244794 | GEO | 2024/07/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [scATAC-seq]

Project description:HBS/AS01 adjuvanted vaccine induces changes in the chromatin structure in monocyte population impacting their gene expression, an effect that lasts until 6 months post vaccination

2024-07-31 | GSE244792 | GEO

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [scRNA-seq]

Project description:HBS/AS01 adjuvanted vaccine induces changes in the chromatin structure in monocytes impacting their gene expression profiles, an effect that lasts until 6 months post vaccination

2024-07-31 | GSE244793 | GEO

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [Nanostring panel]

Project description:HBS/AS01 adjuvanted vaccine induces changes in the chromatin structure of monocytes after vaccination, an effect that lasts until 6 months post vaccination

2024-07-31 | GSE244799 | GEO

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes

Project description:AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes

| PRJNA1024908 | ENA

Transcriptional signatures to AS01-adjuvanted tuberculosis vaccine in naïve and primed participants

Project description:In this exploratory post-hoc analysis of clinical trial samples (clinicalTrials.gov: NCT01424501), we compared gene expression patterns elicited by two immunizations with the candidate tuberculosis (TB) vaccine M72/AS01, between three groups of individuals with different levels of memory responses to TB antigens before vaccination

2022-11-16 | GSE197408 | GEO

Adjuvant associated peripheral-blood mRNA profiles and kinetics induced by the adjuvanted recombinant-protein candidate tuberculosis vaccine M72/AS01 in BCG-vaccinated adults

Project description:Systems biology has the potential to identify gene signatures associated with vaccine immunogenicity or protective efficacy. The main objective of our study was to identify optimal post-vaccination time points for evaluating blood RNA-expression profiles in recipients of the candidate tuberculosis vaccine M72/AS01. In this phase II open-label study (NCT01669096), healthy Bacillus Calmette-Guérin (BCG)-primed, HIV-negative adults were administered two doses (30-days apart) of M72/AS01. Blood samples were collected pre-dose 1, pre-dose 2 and 1, 7, 10, 14, 17 and 30 days post-dose 2. RNA expression in blood and peripheral-blood mononuclear cells (PBMCs) was quantified using microarray technology. The data analysis used as a reference, a PBMC-gene signature that was associated with the protective efficacy of a similarly adjuvanted candidate malaria vaccine. Peripheral-blood CD4+ T-cell reactivity, serum interferon-gamma (IFNG) concentrations and safety were also assessed. Twenty subjects completed the study and 18 subjects received two doses. The observed safety profile was similar to previous trials. Serum IFNG responses and M72-specific CD4+ T cell responses to vaccination were detected as expected, based on previous trial experience. PBMC and whole-blood RNA-expression data at day 14 post-dose 2 relative to pre-vaccination and whole-blood RNA-expression data at 7, 10, and 17 days post-dose 2 relative to pre-vaccination could be used to classify vaccine recipients into gene-signature positive or gene-signature negative groups. In conclusion, whole blood sampled from the 7, 10, 14, or 17 day post-vaccination time points, in addition to pre-vaccination, could be selected to assess potentially clinically relevant responses to M72/AS01 using transcriptome analysis.

2018-03-19 | GSE102459 | GEO

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [RNA-seq]

Project description:AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [RNA-seq]

| PRJNA1024914 | ENA

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [Nanostring panel]

Project description:AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [Nanostring panel]

| PRJNA1024915 | ENA

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [scATAC-seq]

Project description:AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [scATAC-seq]

| PRJNA1024904 | ENA

AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [scRNA-seq]

Project description:AS01-adjuvanted vaccine promotes functional and epigenetic modifications in monocytes [scRNA-seq]